التفاصيل البيبلوغرافية
| العنوان: |
The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation. |
| المؤلفون: |
Patel, Ruchi, Singh, Arushi, Meng, Zhiying, Baldridge, Abigail S., Addison, Daniel, Akhter, Nausheen |
| المصدر: |
Leukemia & Lymphoma; Feb2024, Vol. 65 Issue 2, p168-174, 7p |
| مصطلحات موضوعية: |
ATRIAL fibrillation, ANTICOAGULANTS, STROKE |
| مستخلص: |
For ibrutinib-related atrial fibrillation (IRAF), guidelines for anticoagulation do not exist. We sought to describe stroke, bleeding, and anticoagulation rates among patients with IRAF. We performed a single-center retrospective review of 168 patients treated with ibrutinib followed from 2013 to 2022. Over a median follow-up of 6.4 years, 44 (26.0%) patients developed IRAF of which 38 (86.4%) had a CHA2DS2-VASc ≥2 and 7 (15.9%) had a HAS-BLED ≥3. Anticoagulation was initiated in 20 (45.5%) without a clear pattern in scores, risk factors, or cumulative dose, besides having another reason for anticoagulation. Few patients with IRAF developed non-hemorrhagic CVA (n = 3, 6.8%) or significant bleeding (n = 3, 6.8%). Among those with each adverse outcome, 2 in each group were anticoagulated and all were older than 65 years old. In conclusion, decisions for anticoagulation vary widely and patients who are elderly or with HTN may be most at risk for CVA or significant bleed. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher